Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors

2011187 citationsJournal Articlebronze Open Access

Authors

Giuseppe Giaccone · National Institutes of Health

Arun Rajan · National Institutes of Health

Arlene Berman · National Institutes of Health

Ronan J. Kelly · National Institutes of Health

Éva Szabó · National Institutes of Health

Ariel López-Chávez · National Institutes of Health

Jane B. Trepel

Abstract

Belinostat has modest antitumor activity in this group of heavily pretreated thymic malignancies. However, the duration of response and disease stabilization is intriguing, and additional testing of belinostat in this disease is warranted.

Topics & Keywords

Myasthenia Gravis and Thymoma Histone Deacetylase Inhibitors Research Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 29, Issue 15, pp. 2052-2059

DOI: 10.1200/jco.2010.32.4467

Field-Weighted Citation Impact: 10.67